Financial reports
ARS
2023 FY
Annual report to shareholders
12 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
12 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
27 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
Current reports
8-K
Entry into a Material Definitive Agreement
26 Apr 24
8-K
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
26 Mar 24
8-K
Delcath Systems Announces $7 Million Private Placement
19 Mar 24
8-K
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
19 Mar 24
8-K
Departure of Directors or Certain Officers
14 Feb 24
8-K
Other Events
31 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
13 Nov 23
8-K
Regulation FD Disclosure
6 Sep 23
8-K
HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma
15 Aug 23
Registration and prospectus
D
$7.00 mm in equity / options, sold $7.00 mm, 17 investors
26 Mar 24
S-8
Registration of securities for employees
15 Dec 23
424B3
Prospectus supplement
1 Sep 23
424B3
Prospectus supplement
28 Jun 23
S-3
Shelf registration
14 Jun 23
D
$25.00 mm in equity / options, sold $25.00 mm, 17 investors
31 Mar 23
424B5
Prospectus supplement for primary offering
27 Feb 23
424B3
Prospectus supplement
20 Jan 23
S-3
Shelf registration
10 Jan 23
SC TO-I
Delcath Systems, Inc.
21 Dec 22
Proxies
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
21 Apr 23
DEF 14A
Definitive proxy
4 Apr 22
DEF 14A
Definitive proxy
7 Apr 21
DEF 14A
Definitive proxy
2 Nov 20
PRE 14A
Preliminary proxy
21 Oct 20
DEF 14A
Definitive proxy
19 Aug 19
Other
EFFECT
Notice of effectiveness
29 Jun 23
CORRESP
Correspondence with SEC
26 Jun 23
UPLOAD
Letter from SEC
21 Jun 23
EFFECT
Notice of effectiveness
23 Jan 23
CORRESP
Correspondence with SEC
18 Jan 23
UPLOAD
Letter from SEC
17 Jan 23
EFFECT
Notice of effectiveness
16 Sep 22
CORRESP
Correspondence with SEC
13 Sep 22
UPLOAD
Letter from SEC
12 Sep 22
EFFECT
Notice of effectiveness
19 Oct 21